MedTrace Logo

Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD

NCT04406636 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2022-09-23

No results posted yet for this study

Summary

SHIELD HD is an international, multisite, prospective, longitudinal cohort natural history study to assess the natural history of HD and its biomarkers that are associated with modulation of the number of cytosine-adenine-guanine (CAG) repeats in the mutant Huntingtin (HTT) gene.

Approximately 60 patients will be enrolled into the study and followed for up to 24 months at clinical sites in North America and Europe.

The results of this study will inform assessments for a future interventional treatment trial.

Conditions

  • Huntington Disease

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • CHDI Foundation, Inc.

    lead OTHER

Principal Investigators

  • Anne Rosser, PhD FRCP · Cardiff University

Eligibility

Min Age
18 Years
Max Age
63 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-19
Primary Completion
2023-04-30
Completion
2023-04-30

Countries

  • United States
  • Canada
  • France
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04406636 on ClinicalTrials.gov